Symbols / CMMB
CMMB Chart
About
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.54M |
| Enterprise Value | 753.18M | Income | -10.09M | Sales | — |
| Book/sh | 1.82 | Cash/sh | 0.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -7.75 | PEG | — |
| P/S | — | P/B | 0.85 | P/C | — |
| EV/EBITDA | -69.97 | EV/Sales | — | Quick Ratio | 10.36 |
| Current Ratio | 10.49 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.44 | EPS next Y | -0.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-20 08:00 | ROA | -40.61% |
| ROE | -73.21% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.16M |
| Shs Float | 426.16M | Short Float | 0.27% | Short Ratio | 0.26 |
| Short Interest | — | 52W High | 7.04 | 52W Low | 1.40 |
| Beta | 0.59 | Avg Volume | 89.12K | Volume | 27.96K |
| Target Price | $17.50 | Recom | None | Prev Close | $1.50 |
| Price | $1.55 | Change | 3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.50
Mean price target
2. Current target
$1.55
Latest analyst target
3. DCF / Fair value
$17.50
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$1.55
Low
$10.00
High
$25.00
Mean
$17.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-27 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2025-05-16 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2025-02-20 | main | Maxim Group | Buy → Buy | $7 |
| 2024-11-15 | reit | Oppenheimer | Outperform → Outperform | $11 |
| 2024-05-13 | init | Maxim Group | — → Buy | $4 |
| 2024-05-06 | up | Oppenheimer | Perform → Outperform | $6 |
| 2024-03-08 | main | Oppenheimer | Perform → Perform | — |
| 2023-10-06 | init | Roth MKM | — → Buy | $7 |
| 2023-06-07 | down | Oppenheimer | Outperform → Perform | — |
| 2023-04-18 | main | Oppenheimer | — → Outperform | $7 |
| 2022-03-10 | main | Oppenheimer | — → Outperform | $20 |
| 2021-12-07 | init | Aegis Capital | — → Buy | $30 |
| 2021-05-26 | init | Cantor Fitzgerald | — → Overweight | $45 |
| 2021-05-07 | init | Oppenheimer | — → Outperform | $42 |
- Biotech Chemomab lines up Oppenheimer pitch to investors Feb. 26 - Stock Titan ue, 17 Feb 2026 13
- Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire ue, 17 Feb 2026 13
- Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com Wed, 27 Aug 2025 07
- Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support - TipRanks Fri, 21 Nov 2025 08
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research ue, 14 Oct 2025 07
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - TradingView ue, 14 Oct 2025 07
- Does CMMB have a sustainable dividend - Market Sentiment Report & Weekly Chart Analysis and Guides - mfd.ru Fri, 20 Feb 2026 23
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire hu, 20 Nov 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Wed, 14 Feb 2024 13
- OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - TradingView Fri, 10 Oct 2025 07
- Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat ue, 23 Mar 2021 09
- What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance Wed, 16 Jun 2021 07
- CMMB - Chemomab Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan ue, 23 Mar 2021 19
- Why Is Arrival (ARVL) Stock Up Today? - InvestorPlace ue, 21 Feb 2023 08
- Here's Why We're Not Too Worried About Chemomab Therapeutics' (NASDAQ:CMMB) Cash Burn Situation - Yahoo Finance Fri, 16 Sep 2022 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.02 | 0.00 |
| NormalizedEBITDA | -14.69M | -25.39M | -28.48M | -12.33M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.95M | -24.22M | -27.65M | -12.48M |
| ReconciledDepreciation | 53.00K | 67.00K | 58.00K | 34.00K |
| EBITDA | -14.69M | -25.39M | -28.48M | -12.33M |
| EBIT | -14.74M | -25.46M | -28.53M | -12.37M |
| NetInterestIncome | 794.00K | 1.24M | 353.00K | -111.00K |
| NormalizedIncome | -13.95M | -24.22M | -27.65M | -12.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.95M | -24.22M | -27.65M | -12.48M |
| TotalExpenses | 14.74M | 25.46M | 28.53M | 12.37M |
| RentExpenseSupplemental | 50.00K | 81.00K | 24.00K | 29.00K |
| DilutedAverageShares | 4.06M | 2.94M | 2.84M | 2.59M |
| BasicAverageShares | 4.06M | 2.94M | 2.84M | 2.59M |
| DilutedEPS | -3.44 | -8.24 | -9.68 | -4.80 |
| BasicEPS | -3.44 | -8.24 | -9.68 | -4.80 |
| DilutedNIAvailtoComStockholders | -13.95M | -24.22M | -27.65M | -12.48M |
| NetIncomeCommonStockholders | -13.95M | -24.22M | -27.65M | -12.48M |
| NetIncome | -13.95M | -24.22M | -27.65M | -12.48M |
| NetIncomeIncludingNoncontrollingInterests | -13.95M | -24.22M | -27.65M | -12.48M |
| NetIncomeContinuousOperations | -13.95M | -24.22M | -27.65M | -12.48M |
| TaxProvision | 0.00 | 0.00 | -534.00K | 0.00 |
| PretaxIncome | -13.95M | -24.22M | -28.18M | -12.48M |
| NetNonOperatingInterestIncomeExpense | 794.00K | 1.24M | 353.00K | -111.00K |
| TotalOtherFinanceCost | -794.00K | -1.24M | -353.00K | 111.00K |
| OperatingIncome | -14.74M | -25.46M | -28.53M | -12.37M |
| OperatingExpense | 14.74M | 25.46M | 28.53M | 12.37M |
| ResearchAndDevelopment | 11.33M | 18.38M | 16.98M | 6.33M |
| SellingGeneralAndAdministration | 3.41M | 7.08M | 11.56M | 6.03M |
| GeneralAndAdministrativeExpense | 3.41M | 7.08M | 11.56M | 6.03M |
| OtherGandA | 1.24M | 2.46M | 4.02M | 1.91M |
| InsuranceAndClaims | 538.00K | 648.00K | 1.08M | 1.02M |
| RentAndLandingFees | 50.00K | 81.00K | 24.00K | 29.00K |
| SalariesAndWages | 1.58M | 3.89M | 6.43M | 3.07M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 11.64M | 11.64M | ||
| OrdinarySharesNumber | 377.13M | 284.09M | 221.00M | 228.09M |
| ShareIssued | 377.13M | 284.09M | 232.64M | 228.09M |
| TotalDebt | 324.00K | 392.00K | 214.00K | 343.00K |
| TangibleBookValue | 13.53M | 16.99M | 36.21M | 61.45M |
| InvestedCapital | 13.54M | 17.00M | 36.22M | 61.47M |
| WorkingCapital | 12.82M | 16.06M | 34.99M | 60.04M |
| NetTangibleAssets | 13.53M | 16.99M | 36.21M | 61.45M |
| CapitalLeaseObligations | 324.00K | 392.00K | 214.00K | 343.00K |
| CommonStockEquity | 13.54M | 17.00M | 36.22M | 61.47M |
| TotalCapitalization | 13.54M | 17.00M | 36.22M | 61.47M |
| TotalEquityGrossMinorityInterest | 13.54M | 17.00M | 36.22M | 61.47M |
| StockholdersEquity | 13.54M | 17.00M | 36.22M | 61.47M |
| TreasuryStock | 0.00 | 0.00 | 1.22M | 0.00 |
| RetainedEarnings | -102.62M | -88.68M | -63.82M | -36.17M |
| AdditionalPaidInCapital | 116.16M | 105.67M | 101.26M | 97.64M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.43M | 5.15M | 6.84M | 2.89M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 209.00K | 316.00K | 91.00K | 237.00K |
| LongTermDebtAndCapitalLeaseObligation | 209.00K | 316.00K | 91.00K | 237.00K |
| LongTermCapitalLeaseObligation | 209.00K | 316.00K | 91.00K | 237.00K |
| CurrentLiabilities | 3.22M | 4.84M | 6.75M | 2.65M |
| CurrentDebtAndCapitalLeaseObligation | 115.00K | 76.00K | 123.00K | 106.00K |
| CurrentCapitalLeaseObligation | 115.00K | 76.00K | 123.00K | 106.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 874.00K | 823.00K | 1.56M | 653.00K |
| PayablesAndAccruedExpenses | 2.23M | 3.94M | 5.07M | 1.89M |
| CurrentAccruedExpenses | 1.56M | 3.42M | 3.38M | 555.00K |
| Payables | 666.00K | 516.00K | 1.69M | 1.34M |
| AccountsPayable | 666.00K | 516.00K | 1.69M | 1.34M |
| TotalAssets | 16.96M | 22.15M | 43.06M | 64.35M |
| TotalNonCurrentAssets | 924.00K | 1.25M | 1.33M | 1.67M |
| OtherNonCurrentAssets | 55.00K | |||
| NonCurrentPrepaidAssets | 385.00K | 559.00K | 733.00K | 908.00K |
| InvestmentsAndAdvances | 0.00 | |||
| OtherInvestments | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 6.62K | 8.02K | 14.00K | 14.00K |
| OtherIntangibleAssets | 6.62K | 8.02K | 14.00K | 14.00K |
| NetPPE | 532.38K | 686.98K | 580.00K | 688.00K |
| AccumulatedDepreciation | -271.62K | -220.02K | -165.00K | -107.00K |
| GrossPPE | 804.00K | 907.00K | 745.00K | 795.00K |
| Leases | 14.00K | 14.00K | 16.00K | 16.00K |
| ConstructionInProgress | 14.00K | 14.00K | 14.00K | |
| OtherProperties | 689.00K | 792.00K | 626.00K | 709.00K |
| MachineryFurnitureEquipment | 101.00K | 101.00K | 103.00K | 70.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 16.04M | 20.90M | 41.74M | 62.69M |
| RestrictedCash | 76.00K | 76.00K | 77.00K | 0.00 |
| PrepaidAssets | 1.44M | 748.00K | 1.31M | 1.35M |
| Receivables | 263.00K | 289.00K | 459.00K | 179.00K |
| OtherReceivables | 263.00K | 289.00K | 459.00K | 179.00K |
| CashCashEquivalentsAndShortTermInvestments | 14.27M | 19.78M | 39.89M | 61.16M |
| OtherShortTermInvestments | 8.20M | 10.49M | 26.37M | 45.98M |
| CashAndCashEquivalents | 6.07M | 9.29M | 13.52M | 15.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.39M | -23.61M | -20.44M | -12.61M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -1.22M | 0.00 |
| IssuanceOfCapitalStock | 9.87M | 3.50M | 267.00K | 58.64M |
| CapitalExpenditure | -3.00K | -68.00K | -239.00K | |
| IncomeTaxPaidSupplementalData | 5.00K | 0.00 | ||
| EndCashPosition | 6.15M | 9.37M | 13.60M | 15.24M |
| BeginningCashPosition | 9.37M | 13.60M | 15.24M | 11.73M |
| ChangesInCash | -3.22M | -4.23M | -1.65M | 3.51M |
| FinancingCashFlow | 9.87M | 3.50M | -808.00K | 61.07M |
| CashFlowFromContinuingFinancingActivities | 9.87M | 3.50M | -808.00K | 61.07M |
| NetOtherFinancingCharges | 2.43M | |||
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 143.00K | 10.00K |
| NetCommonStockIssuance | 9.87M | 3.50M | -951.00K | 58.64M |
| CommonStockPayments | 0.00 | 0.00 | -1.22M | 0.00 |
| CommonStockIssuance | 9.87M | 3.50M | 267.00K | 58.64M |
| InvestingCashFlow | 2.30M | 15.88M | 19.53M | -45.19M |
| CashFlowFromContinuingInvestingActivities | 2.30M | 15.88M | 19.53M | -45.19M |
| NetOtherInvestingChanges | 2.30M | 15.88M | 19.60M | -44.95M |
| NetInvestmentPurchaseAndSale | 19.60M | -45.95M | ||
| SaleOfInvestment | 19.60M | |||
| PurchaseOfInvestment | -45.95M | |||
| NetPPEPurchaseAndSale | 0.00 | -3.00K | -68.00K | -235.00K |
| SaleOfPPE | 0.00 | 0.00 | 4.00K | |
| PurchaseOfPPE | 0.00 | -3.00K | -68.00K | -239.00K |
| OperatingCashFlow | -15.39M | -23.61M | -20.37M | -12.37M |
| CashFlowFromContinuingOperatingActivities | -15.39M | -23.61M | -20.37M | -12.37M |
| ChangeInWorkingCapital | -2.11M | -948.00K | 4.01M | -1.95M |
| ChangeInOtherWorkingCapital | 86.00K | -724.00K | 896.00K | 213.00K |
| ChangeInPayablesAndAccruedExpense | -1.71M | -1.13M | 3.17M | -104.00K |
| ChangeInAccruedExpense | -1.86M | 45.00K | 2.82M | -1.28M |
| ChangeInPayable | 150.00K | -1.17M | 352.00K | 1.18M |
| ChangeInAccountPayable | 150.00K | -1.17M | 352.00K | 1.18M |
| ChangeInReceivables | -487.00K | 903.00K | -64.00K | -2.06M |
| StockBasedCompensation | 617.00K | 1.49M | 3.21M | 2.02M |
| DepreciationAmortizationDepletion | 53.00K | 67.00K | 58.00K | 34.00K |
| DepreciationAndAmortization | 53.00K | 67.00K | 58.00K | 34.00K |
| Depreciation | 53.00K | 67.00K | 58.00K | 34.00K |
| NetIncomeFromContinuingOperations | -13.95M | -24.22M | -27.65M | -12.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CMMB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|